AirInSpace Release: Multi-Year Clinical Study Data Suggest Use of FDA-Cleared Mobile Air Decontamination Unit, Plasmairt2006 with HEPA-MD™, Contributes to Reducing Incidence of Airborne Aspergillosis Infection

WASHINGTON--(BUSINESS WIRE)--AirInSpace, a leading supplier of mobile devices that ‘catch and inactivate’ harmful and resistant biological particles from the air, announced today that data from a multi-year clinical study shows a significant reduction in aspergillosis infection rates in a standard hospital setting when using the Company’s patented PlasmairT2006 mobile unit with HEPA-MD™ technology.